Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
US-Based Firm Will Not Rule Out Returning To Market – ‘If Things Change’
Executive Summary
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.
You may also be interested in...
Dr Reddy’s Can Still Go It Alone After Penning Orencia Biosimilar Deal
Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.
Waverley Weighs Its Options With High Costs, Thin Margins
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
Deficient Aseptic Filling And Freeze Drying Hamstring Sandoz’s US Herceptin
Sandoz spoke to Generics Bulletin in the wake of confirming a recent complete response letter for its partnered biosimilar Herceptin candidate in the US.